Ranibizumab for treating diabetic macular oedema

Technology appraisal guidance
Reference number: TA274
Published: 27 February 2013
Last updated: 26 October 2023

History

Background information

TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015 (PDF 68 KB)

Published:

10 April 2015
TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015 (PDF 500 KB)

Published:

23 February 2015
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders (PDF 41 KB)

Published:

23 February 2015
TA274 Macular oedema (diabetic) - ranibizumab: press release information
NICE Single Technology Appraisal process guide (PDF 286 KB)

Published:

06 December 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development (PDF 18 KB)

Published:

02 July 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance (PDF 278 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 138 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis (PDF 189 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK (PDF 67 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB (PDF 28 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD (PDF 14 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS (PDF 108 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health (PDF 8.3 KB)

Published:

04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): comments on the ACD received from the public through the NICE website (PDF 83 KB)

Published:

04 January 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation document information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): evaluation report
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing (PDF 86 KB)

Published:

05 October 2012
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review (PDF 319 KB)

Published:

05 October 2012
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis (PDF 299 KB)

Published:

05 October 2012

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope (PDF 28 KB)

Published:

05 October 2012